Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.…
Horizon Europe-funded HERMOD project launches to support Phase 2 development of HER-096 in Parkinson’s disease
Herantis Pharma (HEL: HRTIS) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 1.330 EUR on 20 November 2026, down 39.5% over 52 weeks. Its 52-week range is 1.036 EUR to 2.870 EUR: the price is 53.7% below the high and 28.4% above the low.
At a market capitalisation of 35.25M EUR, it trades at 66.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 101% for HRTIS.
Herantis Pharma reports return on equity of 392.3%.
It holds more cash than debt, a net cash position of 3.48M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 2.000 EUR is 50.4% above the current price.
No upcoming events tracked.